Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Idarubicin-TACE in Hepatocellular Carcinoma
NCT05280444Phase 3Unknown
- Sponsor
- Zhongda Hospital, Southeast University
- Start
- May 2022
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of idarubicin in hepatocellular carcinoma (HCC), sponsored by Zhongda Hospital, Southeast University. Status: unknown.
02
Drugs
idarubicin
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05280444.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05280444.